Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Lenvatinib|DRUG: Pembrolizumab
Sponsor: University of Illinois at Chicago